Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

Table 3 Adverse event disutilities

Event in VN arm	Utility decrement	Duration (months)	Proportion of patients
Cataract	0.14	1.0	15%
Eye inflammation	0.30	3.6	10%
Increased IOP	0.10^a	1.0	20%

^a Assumption, as no disutility data associated with increased IOP were identified.
AE adverse event, IOP increased intraocular pressure.

ISSN: 1472-6963